Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 10/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | YES1 | P07947 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636518 | 1.00 | SLC40A1 (0.46) | SLC40A1BRAFCCR2EIF2AK3PLK4 | |
| SCHEMBL2193238 | 1.00 | SLC40A1 (0.46) | SLC40A1BRAFCCR2EIF2AK3PLK4 | |
| SCHEMBL2192658 | 0.85 | ERN1 (0.42) | SLC40A1BRAFERN1NR1I2 | |
| SCHEMBL18636304 | 0.85 | ERN1 (0.42) | SLC40A1BRAFERN1NR1I2 | |
| SCHEMBL2192663 | 0.85 | ERN1 (0.42) | SLC40A1BRAFERN1NR1I2 | |
| SCHEMBL1127079 | 0.80 | PKM (0.41) | SLC40A1BRAFPKM | |
| SCHEMBL1127074 | 0.80 | PKM (0.41) | SLC40A1BRAFPKM | |
| SCHEMBL3883014 | 0.79 | GPR35 (0.37) | — | |
| SCHEMBL3883018 | 0.79 | GPR35 (0.37) | — | |
| SCHEMBL1127143 | 0.71 | SLC40A1 (0.46) | SLC40A1BRAFEIF2AK3PLK4EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8642759-B2 | Benzene sulfonamide thiazole and oxazole compounds | GLAXOSMITHKLINE LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-8415345-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo SmithKline LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885BRAF 776/4885CCR2 1517/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885BRAF 776/4885CCR2 1517/4885 |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885BRAF 776/4885CCR2 1517/4885 |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885BRAF 776/4885CCR2 1517/4885 |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885BRAF 776/4885CCR2 1517/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885BRAF 776/4885CCR2 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.